Skip to main content
. Author manuscript; available in PMC: 2012 Dec 10.
Published in final edited form as: Vaccine. 2008 Dec 25;27(7):987–994. doi: 10.1016/j.vaccine.2008.12.002

Table 3.

Enhanced activation of CEA-specific T cells by recombinant yeast expressing an enhancer agonist CEA epitope.

A. Specific release of IFN-γ by CEA-specific T cells stimulated by human DCs treated with yeast-CEA and yeast-CEA-6D (agonist).
DCs Treatment CEA-specific T cells IFN-γ
− − + <15.6
+ Yeast-CEA − <15.6
+ Yeast-CEA-6D − <15.6
+ Yeast-CEA + 508.7
+ Yeast-CEA-6D + 1,501.8
B. Intracellular cytokine staining for IFN-γ of V8T cells stimulated with human DCs treated with yeast-CEA and yeast-CEA-6D (agonist).
Treatment CD3+/CD8+/CD69+/IFN-γ+
Control yeast 0
Yeast-CEA 14.0
Yeast-CEA-6D 20.2

DCs were generated from PBMCs of healthy HLA-A2+ donors and treated at a DC:yeast ratio of 1:5.T cell:APC ratio was 10:1. DCs were treated with yeast-CEA or yeast-CEA-6D and cultured for 48 h, then used to stimulate a CEA-specific T-VLG cell line. Supernatants were harvested after 24 h and screened for production of IFN-γ by ELISA. Results are expressed in pg/ml.

Results are expressed in % of CD3+/CD8+/CD69+/IFN-γ+ T cells of CD8 cells. DCs were generated from PBMCs of healthy HLA-A2+ donor and treated at a DC:yeast ratio of 1:5. T cell:APC ratio was 10:1. DCs were treated with yeast-CEA or yeast-CEA-6D and cultured for 48 h, and then used to stimulate a CEA-specific V8T cell line. Intracellular cytokine staining was performed on the stimulated V8T cells (see Materials and Methods).